NMX1 / NovoMedix - LARVOL DELTA

Targeting CXCR4 via the small molecule inhibitor NMX1 as a therapeutic strategy to treat high-risk malignancies (AACR 2024) - "In animal models of breast cancer, NMX1 effectively prevented tumor growth and metastasis, while also protecting from doxorubicin-induced cardiotoxicity. Our study shows antitumor activity by NMX1 through inhibition of CXCR4, IL-11, and mTOR signaling, providing an effective therapeutic strategy for high-risk and refractory malignancies. Preclinical data on feasible drug combinations and biological correlates of activity support development of early phase clinical studies involving NMX1."

Breast Cancer • Hematological Malignancies • Leukemia • Neuroblastoma • Oncology • Sarcoma • Solid Tumor • CXCL12 • CXCR4 • MET

Novel Interleukin-11 Inhibitors Attenuate Collagen Production in Patient-Derived Synovial Fibroblasts. (PubMed, Cureus) - "Our findings demonstrate a strong connection between IL-11 and synovial fibrosis status in patients with advanced kOA, indicating that IL-11 is a key mediator of this process. The ability of the new NMX compounds to significantly reduce fibrotic markers in patient-derived cells offers a promising preclinical basis for developing targeted therapies to prevent or treat AF attributable to kOA or other arthropathies and traumatic joint injuries."

Journal • Fibrosis • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology • TGFB1

NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TBNC (PRNewswire) - "NovoMedix, LLC...announced that the National Heart, Lung, and Blood Institute division of the NIH has awarded NovoMedix a $2M Phase II SBIR grant to further the development of Novel Small Molecules that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy....NMX1 is a novel, patented, orally available small molecule with excellent safety and PK properties that inhibits mTOR and secretion of IL-11 and activates AMPK."

Financing • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer